Abstract:Key PointsCell-free DNA (cfDNA) is released predominantly by cell death into the bloodstream, although active secretion may have a role. Since the discovery of fetal cfDNA in the maternal circulation, cfDNA analysis has been rapidly implemented in clinical practice for noninvasive prenatal testing.Mutations were first detected in cfDNA more than two decades ago, and interest in circulating tumour DNA (ctDNA) as a noninvasive cancer diagnostic has increased considerably with the development of molecular methods that permit the sensitive detection and monitoring of multiple classes of mutation.ctDNA may have utility at almost every stage of the management of patients with cancer, including diagnosis, minimally invasive molecular profiling, treatment monitoring, the detection of residual disease and the identification of resistance mutations. ctDNA analysis may be broadly considered as a tool both for quantitative analysis of disease burden and for genomic analysis.The identification of ctDNA in individuals before a cancer diagnosis, and in presymptomatic individuals, suggests the possibility of ctDNA analysis as a tool for earlier detection and screening. Noninvasive cancer classification or subtyping has also emerged as a possibility, although for early detection, both technical and biological factors introduce challenges to the detection of mutant DNA in plasma and its interpretation.Monitoring multiple mutations in parallel can enhance the sensitivity of ctDNA detection, can be used to assess the clonal evolution of patients' disease and may identify resistance mutations before clinical progression is observed.ctDNA analysis is beginning to transition from the research setting into the clinic. The US Food and Drug Administration and the European Medicines Agency have approved ctDNA tests for specific indications in the absence of evaluable tumour tissue. Analysis of gene panels in plasma has now become available as a potential clinical tool. Large studies are under way to establish the overall performance and clinical utility of such assays when a tumour biopsy is not available for analysis.Potential applications of ctDNA have been demonstrated by a number of proof-of-principle studies. Prospective clinical trials are beginning to assess the clinical utility of ctDNA analysis for molecular profiling and disease monitoring. The increasing acceptance of ctDNA is enabling the field to move from exploratory ctDNA studies towards clinical trials in which ctDNA guides decision-making.In order to fully exploit the potential utility of liquid biopsies, it is essential that the biology of cfDNA and ctDNA is explored further. The mechanisms of release and degradation, and the factors that affect the representation of ctDNA in plasma, are poorly understood. The nature of ctDNA will be clarified through both large, well-annotated clinical studies and in vivo studies in which variables can be controlled.

Turning the tide of early cancer detection

Liquid biopsy for early cancer detection: technological revolutions and clinical dilemma

Liquid biopsies: the future of cancer early detection

Current and future opportunities for liquid biopsy of circulating biomarkers to aid in early cancer detection

Liquid biopsy: unlocking the potentials of cell-free DNA

Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA

Next-generation sequencing in liquid biopsy: cancer screening and early detection

Liquid biopsy and its role in an advanced clinical trial for lung cancer

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Liquid biopsy: paving a new avenue for cancer research

The Liquid Biopsy Consortium: Challenges and Opportunities for Early Cancer Detection and Monitoring

Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer

Cell-free DNA approaches for cancer early detection and interception

Liquid Biopsy, ctDNA Diagnosis through NGS

Is It Time to Incorporate Liquid Biopsy into High-Risk Cancer Surveillance Protocols in Li–Fraumeni Syndrome?

Toward liquid biopsies in cancer treatment: application of circulating tumor DNA

Circulating Cell-Free DNA for Cancer Early Detection

Liquid Biopsy in the Clinical Management of Cancers

Liquid Biopsies, Novel Approaches and Future Directions

The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments